COVID-19/Obesity

Should patients with obesity be more afraid of COVID-19?

Anna Maria Rychter | Agnieszka Zawada | Alicja Ewa Ratajczak | Agnieszka Dobrowolska | Iwona Krela-Każmierczak

Department of Gastroenterology, Dietetics and Internal Diseases, University of Medical Sciences Poznan, Poznan, Poland

Correspondence
Anna Maria Rychter, Department of Gastroenterology, Dietetics and Internal Diseases, University of Medical Sciences Poznan, Poland, 49 Przybyszewskiego Street, 60-355 Poznan, Poland.
Email: a.m.rychter@gmail.com

Summary
COVID-19 crisis has lasted since the late 2019 to the present day. The severity of the disease is positively correlated with several factors, such as age and coexisting diseases. Furthermore, obesity is increasingly considered as a yet another risk factor, particularly, because it has been observed that people suffering from excessive body weight may experience a more severe course of COVID-19 infection. On the basis of current research, in our nonsystematic review, we have investigated the extent to which obesity can affect the SARS-CoV-2 course and identify the potential mechanisms of the disease. We have also described the role of proper nutrition, physical activity and other aspects relevant to the management of obesity.

KEYWORDS
co-morbidities, COVID-19, obesity, risk factors

1 | INTRODUCTION

The crisis caused by coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019 in Wuhan (capital of Hubei, China) and has spread worldwide in early 2020.1,2 According to World Health Organization (WHO) report of May 16, since the beginning of the outbreak over 4 million cases have been confirmed, more than 300 000 of which have been fatal.3

However, we are also facing another pandemic—the global prevalence of obesity almost tripled between 1975 and 2016, and it is currently estimated that over 2 billion people suffer from excessive body weight.4,5 The current estimates indicate that obesity rates will continue to rise until at least 2030.6 It is generally accepted that obesity is associated with an increased overall mortality, where the life expectancy of an individual suffering from severe obesity is reduced by 5–20 years.7 Moreover, it also increases the risk of developing several co-morbidities, also associated with the severity of the COVID-19 infection, such as cardiovascular disease (CVD), type 2 diabetes (T2DM), kidney disease or numerous types of cancer.8,9 Additionally, obesity also increases the risk of developing pneumonia and other viral respiratory tract infections.10,11

Due to the fact that excessive body weight constitutes a serious global issue, it requires even more attention because it is presumably associated with the severity of the current COVID-19 pandemic. Although the current data are scarce, in our nonsystematic review, we have tried to investigate how many of SARS-CoV-2 patients suffer from obesity and to identify the potential mechanisms which would further explain the association between obesity and SARS-CoV-2 severity. Moreover, we have also described both nutritional and behavioural aspects which could provide a basis for the potential guidelines.

2 | HOW MANY COVID-19 PATIENTS SUFFER FROM OBESITY?

Although the data regarding the impact of SARS-CoV-2 in individuals with obesity are limited and their association has not been fully defined yet, it has been observed that people suffering from excessive
body weight may experience a more serious COVID-19 infection.\textsuperscript{12,13} It is particularly evident in individuals who are affected by other risk factors mentioned earlier, which associated with a more severe course of the disease. This association was also observed during influenza A pandemic in 2009, where obesity was recognized as an independent risk factor of complications. In fact, patients with obesity, following a high-fat diet, suffered over 40% longer than those without excessive body weight.\textsuperscript{14,15} Therefore, it seems that obesity during COVID-19 outbreak requires more attention, especially in the western countries where the prevalence of obesity is high.\textsuperscript{16}

According to the COVID-19-Associated Hospitalization Surveillance Network in the United States at the turn of March 2020, 48% of hospitalized patients presented obesity (range across age groups = 41–59%).\textsuperscript{17} Among patients admitted to the intensive care unit in a French hospital, 47.6% and 28.2% had BMI > 30 kg/m\textsuperscript{2} and BMI > 35 kg/m\textsuperscript{2}, respectively, and obesity constituted a risk factor for COVID-19 severity.\textsuperscript{18} According to the ICNARC (Intensive Care Unit National Audit and Research Centre) report, over 38% of patients at the clinical care unit suffered from obesity, and patients with BMI > 30 died in the critical care units in 57.6% of the cases.\textsuperscript{19} Furthermore, in the study by Petrilli et al\textsuperscript{20} including over 4000 cases, obesity was the strongest predictor of critical illness, substantially higher than pulmonary, or cardiovascular diseases. Similar results were observed in other studies where BMI values were significantly increased in severe cases and non-survivors.\textsuperscript{21–25} Additionally, severe obesity (≥35 kg/m\textsuperscript{2}) was also associated with an increased risk of ICU (intensive care unit) admission among hospitalized patients admitted in the United States.\textsuperscript{26} A summary of obesity prevalence in various research studies and different populations is presented in Table 1.

### 3 | HOW COULD OBESITY AFFECT THE COURSE OF COVID-19?

The receptor for COVID-19, similarly to other coronaviruses, has a high affinity for human angiotensin-converting enzyme-2 (ACE-2), expressed in type 1 and 2 alveolar epithelial cell and endothelium, but also in such organs as the heart, endothelium, pancreas and the intestinal epithelium.\textsuperscript{27} In fact, ACE-2 is considered to be the receptor allowing the entry of COVID-19 into the host cells by means of the activation of the renin-angiotensin-system (RAS).\textsuperscript{28} SARS-CoV-2 affinity for the ACE-2 receptor is higher than in the case of SARS-CoV.\textsuperscript{29} It is vital to point out that the adipose tissue might be prone to SARS-CoV-2 because the expression of ACE-2 is higher in adipose tissue than in the lung tissue.\textsuperscript{15} Nevertheless, there is no current evidence for direct COVID-19 infection of adipose tissue.\textsuperscript{26,30,31} At this point, it should be emphasized that the existing recommendations do not advise a discontinuation of ACE inhibitors and angiotensin receptor blockers, used nowadays as a treatment for hypertension unless the physician recommends otherwise.\textsuperscript{32,33} ‘Cytokine storm’, that is, one of the mechanisms responsible for the severity of COVID-19, is the hyperactivation of the immune system and is associated with an increased level of interleukin (IL)-6, interferon $\gamma$ and other pro-inflammatory cytokines.\textsuperscript{34–36} Taking the abovementioned facts into

### Table 1   BMI values and obesity prevalence among COVID-19 patients

| Data/Location | BMI values and obesity prevalence among COVID-19 patients |
|---------------|----------------------------------------------------------|
| **COVID-NET (14 states), March 1–30, 2020** | **Bodyweight Statistics** |
| 17 | Obesity prevalence—% of total cases |
| | Overall | 18–49 years | 50–64 years | ≥65 years |
| | 48.3% | 59% | 49% | 41% |
| **Four hospitals in the USA** | **ICU admitted** | **Non-ICU admitted** |
| 26 | | 56.8% | 39% |
| 20 | Not hospitalized | Hospitalized | 14.4% | 39.8% |
| **Union Hospital in Wuhan** | **BMI values among different groups** | **Survivors** | **Nonsurvivors** |
| 22 | | General | Critical | >25 among 18.95% of overall | >25 among 88.24% of overall |
| | | 20.0 | 25.50 | | |
| **Jianghan University Hospital** | **General** | **Critical** |
| 21 | | 22.0 | 27.00 |
| **Taizhou Public Medical Center** | **Nonseverely ill** | **Severely ill** |
| 25 | | 23.20 | 24.78 |
| **Three hospitals in Wenzhou** | **Severe cases among healthy weight patients (9.5%)** | **Severe cases among patients with obesity (37.8%)** |
| 23 | | 22.7 | 28.3 |
| | **No invasive mechanical ventilation** | **Invasive mechanical ventilation** |
| 18 | | 27.0 | 31.1 |
account, the adipose tissue synthesizes several proinflammatory adipokines and cytokines which can weaken the immune response and, thus, could constitute the link between obesity and the severity of COVID-19. Furthermore, several adipokines secreted by the adipose tissue are associated, mainly negatively, with pulmonary function. Leptin is involved in the surfactant production and the development of lungs in the neonatal period, but it also participates in the ventilatory drive regulation. Another adipokine-omentin may play a role in the pathogenesis of asthma; however, it can also have a protective effect on the pulmonary endothelial function and decrease pulmonary permeability and inflammation. Reduced omentin, ghrelin and adiponectin levels were observed in individuals suffering from obstructive sleep apnea (OSA). Obesity can also predispose to a greater viral shedding, leading to a greater viral exposure. Because obesity-related co-morbidities are commonly identified among COVID-19 individuals, they can also account for additional risk factors regarding the severity of COVID-19 complications in obesity. Obesity predisposes to several co-morbidities and mechanisms which lead to a more severe course of COVID 19. Although, these co-morbidities were mentioned before, it is crucial to stress that metabolic disorders, such as hypertension, insulin resistance, dyslipidemia or prediabetes, which frequently occur in patients suffering from obesity, also predispose to a poorer COVID-19 outcome.

Furthermore, research studies indicate that individuals suffering from obesity present lower vitamin D levels. In fact, vitamin D could also reduce the cytokine storm—there is also a possible inverse association between the vitamin D level and inflammatory biomarkers, such as IL-6, IL-8, and monocyte chemoattractant protein 1 (MCP-1), although this association has not been entirely confirmed. Moreover, vitamin D could also induce cathelicidins and defensins which can lower the viral replication rate. It remains to be seen if a deficient, or insufficient vitamin D level could constitute another risk factor for COVID-19 severity. On the other hand, vitamin D can modulate the expression of ACE-1 and ACE-2 and have a protective effect on lipopolysaccharide-induced lung damage.

The characteristics of patients with obesity regarding possible factors affecting a more severe COVID-19 course are shown in Table 2.

### 4 | OBESITY, RESPIRATORY DYSFUNCTIONS AND COVID-19

Most of the COVID-19 patients present symptoms of a respiratory disease. Hospitalization rates and the number of respiratory infections are higher in individuals with obesity than in normal-weight patients. There are several respiratory dysfunctions and impaired respiratory mechanisms associated with obesity which can deteriorate the course of SARS-CoV-2. First of all, patients with obesity have an increased airway exchange and impaired gas exchange. An excessive adipose tissue amount in the abdominal area can decrease diaphragmatic excursion and impair ventilation of the base of the lung, which in turn can lead to the reduced blood oxygen saturation. Additionally, both lung volume and muscle strength are lower among patients with obesity. In the study conducted by Jones et al., an increased BMI exponentially decreased the functional residual capacity (FRC) and expiratory reserve volume (ERV) among patients with obesity and were equal to 47% and 75% of the values for lean individuals, respectively. Vital capacity and total lung capacity can also be decreased among patients with extreme obesity. Secondly, obesity is linked to asthma, chronic obstructive pulmonary disease (COPD), obesity hypoventilation syndrome (OHS), pulmonary hypertension and OSA. Moreover, excessive body weight also impairs the course of acute respiratory distress syndrome (ARDS) and COPD, as well as impacts pulmonary function during acute episodes. Obesity also increases the risk of hypoventilation syndrome in the ICU individuals and can lead to a respiratory failure when ARDS is present. Furthermore, not only has leptin been

### TABLE 2 The characteristic of patients with obesity-associated with high risk and worse outcome of COVID-19

| Pulmonary function | Pulmonary oedema, lung damage, increased pulmonary vascular permeability, impaired gas exchange, reduced oxygen saturation of blood, decreased ERV and FRC, lower muscle strength, lower lung volume |
|--------------------|--------------------------------------------------------------------------------------------------|
| Co-morbidities     | Atherosclerosis, cancer, epicardial adipose tissue inflammation, asthma, ARDS, OSAS, COPD, T2DM, CVD |
| Metabolic          | Hypertension, insulin resistance, prediabetes, dyslipidemia                                     |
| abnormalities      |                                                                                                 |
| Adipokines and     | TNF-α, IL-6, IL-8, CRP, MCP-1, leptin, adiponectin, omentin                                     |
| cytokines          |                                                                                                 |
| Vitamin D status   | Usually deficient or insufficient level                                                          |

Abbreviations: ERV, expiratory reserve volume; FRC, functional residual capacity; ARDS, acute respiratory distress syndrome; T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease; OSAS, obstructive sleep apneas; COPD, chronic obstructive pulmonary disease; TNF-α, tumour necrosis factor α; IL-6, interleukin 6; CRP, C-reactive protein; MCP-1, monocyte chemoattractant protein 1; | higher among patients suffering from obesity; | lower among patients suffering from obesity.
involved in the physiological but also in the pathological conditions of the respiratory system, such as COPD, OSA and asthma. In fact, due to high leptin levels among patients with obesity, leptin resistance can be the result of upregulation of SOCS-3, which also negatively regulates antiviral interferons (IFNs) signalling. Furthermore, IFN deficiency might constitute the link between the risk factors, such as obesity, and the severity of pulmonary disorders.

5 | OBESITY PARADOX AND COVID-19

Several studies demonstrated that individuals with excessive body weight had improved survival rates, or a chronic disease prognosis, for example, of CVD when compared with healthy body weight individuals. This phenomenon was called 'the obesity paradox' and, according to CVD disease, it may relate to even 30% of patients with obesity. Whether the obesity paradox will be present among COVID-19 patients remains to be seen, nevertheless, the phenomenon was reported among other respiratory diseases, such as COPD or ARDS. Its pathophysiological basis remains unknown; however, an increased BMI seems to be associated with a better survival and a slower decline in the lung function in patients with a mild course of chronic obstructive pulmonary disease. It may be partially explained by the fact that a severe form of COPD can lead to weight loss and later to cachexia—it would seem that obesity would prevent this. Moreover, the obesity paradox in COPD could also be explained by adipokines, because certain individuals can have a more 'favourable' adipokine profile. Regardless of the obesity paradox in COPD, a low-energy diet which leads to weight loss, combined with physical activity, is still recommended among patients with obesity and respiratory disorders. It alleviates the symptoms and improves the functional capacity and strength, as well as helps to maintain a free-fat mass.

6 | WHAT GUIDELINES SHOULD WE FOLLOW?

To the best of our knowledge, there are no specific guidelines concerning the nutritional treatment of COVID-19 patients with obesity. However, such organizations as WHO, or The European Association for the Study of Obesity (EASO) have prepared nutritional guidelines and tips regarding nutrition during quarantine. It seems obvious that because obesity possibly is associated with the severity of COVID-19, it is recommended to apply a hypocaloric diet to reduce body weight. What is more, weight loss is also beneficial in terms of lung function. Several behavioural and nutritional aspects could be essential among patients with obesity, and they should be considered when preparing future guidelines.

On the basis of the existing knowledge, an adequate intake of vitamins A, E, B3, B6, B12, D, and folate, as well as zinc, copper, selenium, iron, and omega-3 polyunsaturated fatty acids is essential for the maintenance of proper immune function. Although micronutrient insufficiency and nutritional status increase the risk of COVID-19 infection and could worsen its outcome, the use of supraphysiologic amounts to improve the course of COVID-19 is not currently recommended. However, studies have demonstrated that the intake of several vitamins and micronutrients, such as vitamin A, C, B1, potassium, magnesium, calcium, or iron is usually insufficient in patients suffering from obesity and therefore should be taken into account. Whether vitamin D supplementation should be increased in COVID-19 period remains unclear and is not currently recommended. In fact, more randomized-controlled trials should be performed to confirm these suggestions.

It has been shown that a high consumption of saturated fatty acids (SFAs) can induce lipotoxic state, cause adipose tissue inflammation and promote the activation of the innate immune system due to the activation of toll-like receptor 4 (TLR-4). In the animal model, a high-fat diet induced MCP-1 for macrophage infiltration into the lung tissue and an increased lipopolysaccharide induced interleukin-1β and tumour necrosis factor α (TNFα) production. A high intake of both protein and fat may be associated with higher levels of plasma interleukin-6 and TNFα. However, the interaction between nutrition and immunity is extensive and very complex; thus, more randomized-controlled trials should be conducted in this area.

Psychosocial burdens, for example, stress or depression, have been associated with obesity, and a psychological support is an essential approach to managing obesity. During COVID-19 pandemic, increased psychological distress was observed both in infected individuals and in the general population. Additionally, social isolation was found to be a predictor of an increased mortality, as well as a possible cause of depression and anxiety in the youth. It is worth noticing that individuals suffering from obesity are usually more vulnerable to distress and psychological impact of COVID-19 quarantine can influence the proper obesity management. Psychological distress can also lead to a binge and emotional eating among bariatric surgery patients (in time before or after the surgery), which can be associated with poorer long-term results. However, the association between psychological aspects and obesity during the current epidemiological situation needs to be further investigated; psychological support should definitely constitute one of the elements of the proper obesity management during COVID-19 pandemic.

Although the recent statistics are limited, it could be assumed that during the prolonged SARS-CoV-2 quarantine the level of physical activity is lower than usual. In fact, physical inactivity not only predisposes to weight gain but can also lead to the loss of strength, skeletal muscle mass and immune competence. It is vital to bear in mind that quarantine reduced the physical activity level not only for habitually physically active individuals but also for those whose activity was associated with work, or school, as well as those who mainly work physically. Physical activity has a positive effect on lung function; it lowers the risk of respiratory infections and may partially counteract binding of COVID-19 to the ACE-2 receptor. Therefore, moderate to vigorous physical activity, but not of high intensity, should be recommended as a supporting, preventive component, particularly for patients with obesity among whom additional weight gain can lead to...
serious health consequences, including rapid loss of FRC and ERV.\textsuperscript{5,6,7,9,6}

7 CONCLUSIONS

- New observational studies indicate that higher BMI values are significantly increased in patients with severe course of the disease and nonsurvivors.
- Considering the existing knowledge, behavioural management of obesity, including weight loss, should be considered as one of the targets for preventing care and viable strategy, especially during COVID-19 pandemic.
- We strongly advise to perform the measurement of body weight (with the assessment of adipose tissue) in every COVID-19 patient, because obesity deteriorates the infection course and is associated with an increased mortality among COVID-19 patients. Additionally, guidelines on nutritional and behavioural support among COVID-19 patients with obesity are necessary.
- At this point, it is not known what kind of chronic medical conditions, and if any, will be seen in COVID-19 recovery individuals. It could be suggested that quite a few of them may need a special dietary treatment and behavioural interventions. Moreover, post ventilation-acquired dysphagia in SARS-CoV-2 survivors could be a challenge and will require a special nutritional support.

ACKNOWLEDGEMENT

We would like to thank the TranslationLab, a biomedical translation company, for linguistic proofreading.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ORCID

Anna Maria Rychter  https://orcid.org/0000-0002-6586-3611
Agnieszka Zawada  https://orcid.org/0000-0001-6995-090X
Alicja Ewa Ratajczak  https://orcid.org/0000-0002-7731-6965
Agnieszka Dobrowolska  https://orcid.org/0000-0002-3647-5070
Iwona Krela-Kaźmierczak  https://orcid.org/0000-0001-5122-8003

REFERENCES

1. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: The Species and Its Viruses – a Statement of the Coronavirus Study Group. Microbiology. 2020;536–544. https://doi.org/10.1101/2020.02.07.937862
2. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):612–632. https://doi.org/10.1016/j.ijantimicag.2020.105924
3. World Health Organization. Coronavirus disease (COVID-19). Situation report—118.
4. Smith KB, Smith MS. Obesity statistics. Prim Care. 2016;43(1):121-135, ix. https://doi.org/10.1016/j.pop.2015.10.001
5. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298. https://doi.org/10.1038/s41574-019-0176-8
6. Obesity Update 2017.
7. Abdelal A, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161-161. https://doi.org/10.21037/atm.2017.03.107
8. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
9. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med. 2020;23(4):268-271. https://doi.org/10.34172/aim.2020.09
10. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol Published Online April. 2020;23:341–342. https://doi.org/10.1038/s41574-020-0364-6
11. Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties. Clin Pharmacokinet. 2020;1–11. https://doi.org/10.1007/s40262-020-00891-1
12. Puíg-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020;68(1):2-5. https://doi.org/10.1016/j.s1220-020-02294-5
13. Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. Published online April 27, 2020;1–2, cob.12365. https://doi.org/10.1111/cob.12365
14. Milner JJ, Rebeles J, Dhungana S, et al. Obesity increases mortality and modulates the lung metabolome during pandemic H1N1 influenza virus infection in mice. J Immunol. 2015;194(10):4846-4859. https://doi.org/10.4049/jimmunol.1402295
15. Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev Published Online April 13, 2020;21(6):e13034–e13036. https://doi.org/10.1111/obr.13034
16. Ryan DH, Ravussin E, Heymsfield S. COVID-19 and the patient with obesity—the editors speak out. Obesity. 2020;28(5):847-847. https://doi.org/10.1002/oby.22808
17. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-19, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. https://doi.org/10.15585/mmwr.mm6915e3
18. Simonnet A, Chettboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;1–5. https://doi.org/10.1002/oby.22831
19. House N, Holborn H, WC L. ICNARC report on COVID-19 in critical care. ICNARC. 2020:171–26.
20. Petrelli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. Intensive Care and Critical Care Medicine. 2020;1–25. https://doi.org/10.1001/2020.04.08.20057794
21. Liu M, He P, Liu H, et al. Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia. Chin J Tuberc Respir Dis. 2020;43:209–214. E016. https://doi.org/10.3769/j.issn.1001-0939.2020.0016
22. Peng J, Xiao X, Hu M, Zhang X. Interaction between gut microbiome and cardiovascular disease. Life Sci. 2018;214:153-157. https://doi.org/10.1016/j.lfs.2018.10.063
23. Zheng KI, Gao F, Wang X-B, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. Published Online April 2020;108:e154244-e154247. https://doi.org/10.1016/j.metabol.2020.154244
24. Huang J-F, Wang X-B, Zheng KI, et al. Obesity hypoventilation syndrome and severe COVID-19. Metabolism. 2020;108:e154249-e154252. https://doi.org/10.1016/j.metabol.2020.154249

25. Chen Q, Zheng Z, Zhang C, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020;1-9. https://doi.org/10.1007/s15010-020-01432-5

26. Kalligeros M, Shehadeh F, Mylona EK, et al. Association of obesity with disease severity among patients with COVID-19. Obesity. Published online April 30, 2020;1-5, e22859. https://doi.org/10.1002/oby.22859

27. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of COVID-19 infection with reference to use of therapeutic and other drugs used in co-morbid diseases (hypertension, diabetes etc). Diabetes Metab Syndr Clin Res Rev. 2020;14(3):251-254. https://doi.org/10.1016/j.dsrcr.2020.03.012

28. Malavazos AE, Kosmidou MM, Bandera F, Iacobellis G. Targeting the adipose tissue in COVID-19. Obesity. Published online April 21, 2020;1-2, e22844. https://doi.org/10.1002/oby.22844

29. Petrosillo N, Vicceonte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. Published online March 2020;26(6):729–734. S1198743X20301713. https://doi.org/10.1016/j.cmi.2020.03.026

30. Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in COVID-19. Obesity. Published online April 21, 2020;1-4, e22843. https://doi.org/10.1002/oby.22843

31. Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity. Published online April 27, 2020;1-5, e22856. https://doi.org/10.1002/oby.22856

32. Patients taking ACE-I and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. American Heart Association. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advise-by-their-physician

33. HFSA/ACC/AHA Statement Addresses Concerns Re: using RAAS antagonists in COVID-19 - American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aaha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19

34. Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Obesity: the "Achilles heel" for COVID-19? Metabolism. 2020;108:e154251-e154254. https://doi.org/10.1016/j.metabol.2020.154251

35. Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnessi L. Obesity and SARS-CoV-2: a population to safeguard. Metabolism. Published online April 16, 2020;1-2, e22838. https://doi.org/10.1016/j.metabol.2020.04.112

36. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. https://doi.org/10.1038/s41418-020-0530-3

37. Sattar N, Mclnnes IB, McMurray JJV. Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;1-8. https://doi.org/10.1161/CIRCULATIONAHA.120.047659

38. Melo LC, da Silva MAM, Caldes ACDN. Obesity and lung function: a systematic review. Einstein Sao Paulo. 2014;12(1):120-125. https://doi.org/10.1590/S1679-45082014RW2691

39. Oh Y-M, Jeong B-H, Woo S-Y, et al. Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression. Ann am Thorac Soc. 2015;12(7):1005-1012. https://doi.org/10.1513/AnnalsATS.201501-005OC

40. Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755-767. https://doi.org/10.1080/17476348.2018.1506331
Food and nutrition tips during self-quarantine. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/technical-guidance/food-and-nutrition-tips-during-self-quarantine

Mancuso P. Obesity and respiratory infections: does excess adiposity weigh down host defense? Palm Pharmacol Ther. 2013;26(4):412-419. https://doi.org/10.1016/j.pupt.2012.04.006

Xia JY, Lloyd-Jones DM, Khan SS. Association of body mass index with mortality in cardiovascular disease: new insights into the obesity paradox from multiple perspectives. Trends Cardiovasc Med. 2019;29(4):220-225. https://doi.org/10.1016/j.tcm.2018.08.006

Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120(10):863-870. https://doi.org/10.1016/j.amjmed.2007.05.011

Vecchiet A, Dallegri F, Carbone F, et al. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6-17. https://doi.org/10.1016/j.ejim.2017.10.020

Brun J-F, Varlet-Marie C, Fedou C, Raynaud de Mauverger E. Are obesity phenotypes and their obesity types associated with cardiovascular diseases? Eur J Clin Invest. 2019;49(2):236-246. https://doi.org/10.1111/eci.13486

Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97(7):2482-2488. https://doi.org/10.1210/jc.2011-3475

Jose RJ, Manuel A. Does COVID-19 disprove the obesity paradox in ARDS? Obesity. Published Online April 15, 2020;28(6):1007-1007. https://doi.org/10.1002/oby.22835

Guennette JA, Jensen D, O’Donnell DE. Respiratory function and the obesity paradox. Curr Opin Clin Nutr Metab Care. 2010;13(6):618-624. https://doi.org/10.1097/MCO.0b013e32833e3453

Sun Y, Milne S, Jaw JE, et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res. 2019;20(1):236-246. https://doi.org/10.1186/s12931-019-1209-5

McDonald VM, Gibson PG, Scott HA, et al. Should we treat obesity in COPD? The effects of diet and resistance exercise training: treating the obesity paradox. Respir Physiol. 2016;215(5):875-882. https://doi.org/10.10111/resp.12746

Practical advice on maintaining health during COVID-19 pandemic. Energy intake.

Practical advice on supporting health during the COVID-19 pandemic. Healthy hydration.

Muscogiuri G, Barrea L, Savastano S, Colao A. Nutritional recommendations for CoVID-19 quarantine. Eur J Clin Nutr. 2020;74:850-851. https://doi.org/10.1038/s41430-020-0635-2

Food and nutrition tips during self-quarantine. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/technical-guidance/food-and-nutrition-tips-during-self-quarantine

Robinson PD. Obesity and its impact on the respiratory system. Paediatr Respir Rev. 2014;15(3):219-226. https://doi.org/10.1016/j.prrv.2014.06.003

Naja F, Hamadeh R. Nutrition amid the COVID-19 pandemic: a multi-level framework for action. Eur J Clin Nutr. 2020;1-5. https://doi.org/10.1038/s41430-020-0634-3

t-e Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176-e1001186. https://doi.org/10.1371/journal.ppat.1001176

Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients. 2020;12(4):1181-1191. https://doi.org/10.3390/nu12041181

Gasmi A, Noor S, Tippaitore T, Dedar M, Menzel A, Bjerkland G. Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. Clin Immunol. Published Online April 2020; 215:e108409-108418. https://doi.org/10.1016/j.clim.2020.108409

Barazzoni R, Bischoff SC, Breda J, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. Published Online March 2020; 50261561420301400. 39(6):1631-1638. https://doi.org/10.1016/j.clnu.2020.03.022

Rychter AM, Ratajczak AE, Zawada A, Dobrowolska A, Krela-Kazmierczak I. Non-systematic review of diet and nutritional risk factors of cardiovascular disease in obesity. Nutrients. 2020;12(3):814-831. https://doi.org/10.3390/nu12030814

Han JE, Jones JL, Tangpricha V, et al. High dose vitamin D administration in ventilated intensive care unit patients: a pilot double blind randomized controlled trial. J Clin Transl Endocrinol. 2016;4:59-65. https://doi.org/10.1016/j.jteint.2016.04.004

Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun. Published Online April 2020;30537-30539, S0889159120305377. https://doi.org/10.1016/j.bbi.2020.04.040

Ruiz-Nuñez B, Dijck-Brouwer DAJ, Muskiet FAJ. The relation of saturated fatty acids with low-grade inflammation and cardiovascular disease. J Nutr Biochem. 2016;36:1-20. https://doi.org/10.1016/j.jnutbio.2015.12.007

Tashiro H, Takahashi K, Sadamatsu H, et al. Saturated fatty acid increases lung macrophages and augments house dust mite-induced airway inflammation in mice fed with high-fat diet. Inflammation. 2017;40(3):1072-1086. https://doi.org/10.1017/s1073537517300552-0

Chmurszynska A, Muzsik A, Krzyżanowska-Jankowska P, Walkowiak J, Bajerska J. The effect of habitual fat intake, IL6 polymorphism, and different diet strategies on inflammation in postmenopausal women with central obesity. Nutrients. 2019;11(7):1557–1569. https://doi.org/10.3390/nu11071557

Venter C, Eyriger S, Sarin T, Klatt KC. Nutrition and the immune system: a complicated tango. Nutrients. 2020;12(3):818-833. https://doi.org/10.3390/nu12030818

Tomiyama A. Stress and obesity. Annu Rev Psychol. 2018;16:703-718.

Zhang J, Lu H, Zeng H, et al. The differential psychological distress of populations affected by the COVID-19 pandemic. Brain Behav Immun. Published Online April 2020;30535-30539, S0889159120305377. https://doi.org/10.1016/j.bbi.2020.04.031

Buttell M, Relikoff D, Jutte D, Syme SL, Balmes J, Adler N. Social isolation: a predictor of mortality comparable to traditional clinical risk factors of cardiovascular disease in obesity. Eur J Clin Nutr. 2020;74:850-851. https://doi.org/10.1038/s41430-020-0634-3

Lippi G, Henry BM, Bovo C, Sanchis-Gomar F. Health risks and potential remedies during prolonged lockdowns for coronavirus disease 2019 (COVID-19). Diagnosi. 2020;7(2):85-90. https://doi.org/10.1515/dx-2020-0041
94. Sockalingam S, Leung SE, Cassin SE. The impact of COVID-19 on bariatric surgery: re-defining psychosocial care. Obesity. Published Online April 15, 2020. (6):1010-1012. https://doi.org/10.1002/oby.22836

95. Zbinden-Foncea H, Francaux M, Deldicque L, Hawley JA. Does high cardiorespiratory fitness confer some protection against pro-inflammatory responses after infection by SARS-CoV-2? Obesity. Published online April 23, 2020;1-14, oby.22849. https://doi.org/10.1002/oby.22849

96. Rahmati-Ahmadabad, S, Hosseini, F. Exercise against SARS-CoV-2 (COVID-19): Does workout intensity matter? (A mini review of some indirect evidence related to obesity). Obesity Medicine. 2020; e100245. https://doi.org/10.1016/j.obmed.2020.100245

How to cite this article: Rychter AM, Zawada A, Ratajczak AE, Dobrowolska A, Krela-Każmierczak I. Should patients with obesity be more afraid of COVID-19? Obesity Reviews. 2020; 21:e13083. https://doi.org/10.1111/obr.13083